Valuation: Verastem, Inc.

Market Cap 53Cr 46Cr 43Cr 40Cr 74Cr 5.06TCr 76Cr 513.65Cr 200.88Cr 2.5TCr 198.28Cr 193.98Cr 8.65TCr P/E 2026 *
-3.8x
P/E 2027 * -5.36x
Enterprise Value 36Cr 32Cr 30Cr 27Cr 51Cr 3.48TCr 52Cr 353.17Cr 138.12Cr 1.72TCr 136.33Cr 133.37Cr 5.95TCr EV / Sales 2026 *
3.56x
EV / Sales 2027 * 1.79x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-3.53%
1 week+2.04%
Current month+57.33%
1 month+57.33%
3 months+11.30%
6 months-6.24%
Current year-22.15%
1 week 5.82
Extreme 5.82
6.46
1 month 3.84
Extreme 3.835
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06/26 Sell

Chief Financial Officer

-4,089 0.0066%
22/06/26 Sell

Chief Executive Officer

-20,871 0.0339%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%+2.04%-4.45%-41.65% 53Cr
-2.29%-4.89%+44.88%+65.86% 5.52TCr
+2.83%+0.48%+28.18%+82.59% 5.56TCr
+0.54%+1.22%-16.62%-13.47% 2.35TCr
-0.97%-3.30%-1.79%+383.00% 2.24TCr
-4.01%-3.67%+13.17%-14.29% 2.06TCr
-1.61%-3.68%+25.32%-34.19% 1.74TCr
-3.34%-7.77%+23.78%+536.66% 1.52TCr
-2.09%+0.64%+49.78%+178.74% 1.39TCr
-3.14%-8.47%+165.37%+292.18% 1.37TCr
Average -1.76%-0.76%+32.76%+143.54% 2.38TCr
Weighted average by Cap. -0.90%-0.51%+32.13%+126.85%

Financials

2026 *2027 *
Net sales 10Cr 8.95Cr 8.36Cr 7.67Cr 14Cr 975.76Cr 15Cr 99Cr 39Cr 482.85Cr 38Cr 37Cr 1.67TCr 18Cr 16Cr 15Cr 13Cr 25Cr 1.71TCr 26Cr 173.46Cr 68Cr 845.33Cr 67Cr 66Cr 2.92TCr
Net income -17Cr -15Cr -14Cr -12Cr -23Cr -1.59TCr -24Cr -160.99Cr -63Cr -784.55Cr -62Cr -61Cr -2.71TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.36TCr -21Cr -138.17Cr -54Cr -673.35Cr -53Cr -52Cr -2.33TCr
Net Debt -16Cr -14Cr -14Cr -12Cr -23Cr -1.58TCr -24Cr -160.48Cr -63Cr -782.06Cr -62Cr -61Cr -2.7TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2.01TCr -30Cr -203.86Cr -80Cr -993.46Cr -79Cr -77Cr -3.43TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
29/26/29 $6.010 -3.53% 22,49,888
28/26/28 $6.230 +2.47% 12,75,019
27/26/27 $6.080 +0.50% 22,44,215
24/26/24 $6.050 -2.10% 25,31,721
23/26/23 $6.180 +4.92% 21,93,680
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.010USD
Average target price
15.00USD
Spread / Average Target
+149.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock